London · Delayed Price · Currency is GBP · Price in GBX Hemogenyx Pharmaceuticals Statistics
Total Valuation
LON:HEMO has a market cap or net worth of GBP 53.01 million. The enterprise value is 53.37 million.
| Market Cap | 53.01M |
| Enterprise Value | 53.37M |
Important Dates
The next estimated earnings date is Friday, June 26, 2026.
| Earnings Date | Jun 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LON:HEMO has 6.80 million shares outstanding. The number of shares has increased by 34.57% in one year.
| Current Share Class | 6.80M |
| Shares Outstanding | 6.80M |
| Shares Change (YoY) | +34.57% |
| Shares Change (QoQ) | +51.29% |
| Owned by Insiders (%) | 18.79% |
| Owned by Institutions (%) | 56.04% |
| Float | 5.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 46.31 |
| P/TBV Ratio | 52.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 1.75.
| Current Ratio | 1.38 |
| Quick Ratio | 1.09 |
| Debt / Equity | 1.75 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.58 |
| Interest Coverage | -30.38 |
Financial Efficiency
Return on equity (ROE) is -977.71% and return on invested capital (ROIC) is -131.56%.
| Return on Equity (ROE) | -977.71% |
| Return on Assets (ROA) | -103.92% |
| Return on Invested Capital (ROIC) | -131.56% |
| Return on Capital Employed (ROCE) | -257.66% |
| Weighted Average Cost of Capital (WACC) | 12.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -610,023 |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +316.90% in the last 52 weeks. The beta is 1.50, so LON:HEMO's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | +316.90% |
| 50-Day Moving Average | 768.01 |
| 200-Day Moving Average | 854.94 |
| Relative Strength Index (RSI) | 55.54 |
| Average Volume (20 Days) | 16,941 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.97M |
| Pretax Income | -9.77M |
| Net Income | -9.76M |
| EBITDA | -6.78M |
| EBIT | -6.97M |
| Earnings Per Share (EPS) | -2.20 |
Balance Sheet
The company has 1.59 million in cash and 2.00 million in debt, with a net cash position of -417,816 or -0.06 per share.
| Cash & Cash Equivalents | 1.59M |
| Total Debt | 2.00M |
| Net Cash | -417,816 |
| Net Cash Per Share | -0.06 |
| Equity (Book Value) | 1.14M |
| Book Value Per Share | 0.20 |
| Working Capital | 564,875 |
Cash Flow
In the last 12 months, operating cash flow was -3.45 million and capital expenditures -3,921, giving a free cash flow of -3.45 million.
| Operating Cash Flow | -3.45M |
| Capital Expenditures | -3,921 |
| Depreciation & Amortization | 188,926 |
| Net Borrowing | -632,575 |
| Free Cash Flow | -3.45M |
| FCF Per Share | -0.51 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:HEMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.57% |
| Shareholder Yield | -34.57% |
| Earnings Yield | -18.41% |
| FCF Yield | -6.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.0025.
| Last Split Date | Dec 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0025 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |